{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:18:35Z","timestamp":1770358715207,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/bmt.2015.338","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T14:53:26Z","timestamp":1452524006000},"page":"771-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation"],"prefix":"10.1038","volume":"51","author":[{"given":"J","family":"Finke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Schmoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hackanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"key":"BFbmt2015338_CR1","first-page":"1037","volume":"15","author":"EG Levine","year":"1986","unstructured":"Levine EG, Bloomfield CD . Secondary myelodysplastic syndromes and leukaemias. Clin Haematol 1986; 15: 1037\u20131080.","journal-title":"Clin Haematol"},{"key":"BFbmt2015338_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11912-007-0050-z","volume":"9","author":"G Borthakur","year":"2007","unstructured":"Borthakur G, Estey AE . Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep 2007; 9: 373\u2013377.","journal-title":"Curr Oncol Rep"},{"key":"BFbmt2015338_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/pbc.21931","volume":"53","author":"BH Kushner","year":"2009","unstructured":"Kushner BH, Kramer K, Modak S, Qin LX, Yataghena K, Jhanwar SC et al. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009; 53: 17\u201322.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbmt2015338_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bmt.1704124","volume":"32","author":"R Howe","year":"2003","unstructured":"Howe R, Micallef IN, Inwards DJ, Ansell SM, Dewald GW, Dispenzieri A et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003; 32: 317\u2013324.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015338_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.bbmt.2007.01.079","volume":"13","author":"P Armand","year":"2007","unstructured":"Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007; 13: 655\u2013664.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015338_CR6","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","volume":"115","author":"MR Litzow","year":"2010","unstructured":"Litzow MR, Tarima S, P\u00e9rez WS, Bolwell BJ, Cairo MS, Camitta BM et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850\u20131857.","journal-title":"Blood"},{"key":"BFbmt2015338_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3324\/haematol.2008.000927","volume":"94","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94: 542\u2013549.","journal-title":"Haematologica"},{"key":"BFbmt2015338_CR8","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","volume":"96","author":"ML Slovak","year":"2000","unstructured":"Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075\u20134083.","journal-title":"Blood"},{"key":"BFbmt2015338_CR9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.bbmt.2009.08.002","volume":"15","author":"H Bertz","year":"2009","unstructured":"Bertz H, Spyridonidis A, W\u00e4sch R, Gr\u00fcllich C, Egger M, Finke J . A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transplant 2009; 15: 1563\u20131570.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015338_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855\u2013864.","journal-title":"Lancet Oncol"},{"key":"BFbmt2015338_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855\u2013864.","journal-title":"Br J Haematol"},{"key":"BFbmt2015338_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204\u2013217.","journal-title":"Am J Med"},{"key":"BFbmt2015338_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2000.18.5.963","volume":"18","author":"I Yakoub-Agha","year":"2000","unstructured":"Yakoub-Agha I, de La Salmoni\u00e8re P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963\u2013971.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015338_CR14","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1200\/JCO.2001.19.8.2134","volume":"19","author":"RP Witherspoon","year":"2001","unstructured":"Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR . Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001; 19: 2134\u20132141.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015338_CR15","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/bmt.2010.20","volume":"45","author":"P Armand","year":"2010","unstructured":"Armand P, Kim HT, Mayer E, Cutler CS, Ho VT, Koreth J et al. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant 2010; 45: 1611\u20131617.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015338_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","volume":"40","author":"S Bhatia","year":"2013","unstructured":"Bhatia S . Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 2013; 40: 666\u2013675.","journal-title":"Semin Oncol"},{"key":"BFbmt2015338_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/bmt.2015.10","volume":"50","author":"J Steinmann","year":"2015","unstructured":"Steinmann J, Bertz H, W\u00e4sch R, Marks R, Zeiser R, Bogatyreva L et al. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. Bone Marrow Transplant 2015; 50: 690\u2013695.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015338_CR18","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1002\/cncr.25500","volume":"116","author":"M de Lima","year":"2010","unstructured":"de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116: 5420\u20135431.","journal-title":"Cancer"},{"key":"BFbmt2015338_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","volume":"26","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381\u2013389.","journal-title":"Leukemia"},{"key":"BFbmt2015338_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/156800913804486656","volume":"13","author":"H Reikvam","year":"2013","unstructured":"Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersv\u00e6r E et al. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Curr Cancer Drug Targets 2013; 13: 30\u201347.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFbmt2015338_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fimmu.2015.00036","volume":"6","author":"A Di Stasi","year":"2015","unstructured":"Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K . Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 2015; 6: 36.","journal-title":"Front Immunol"},{"key":"BFbmt2015338_CR22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/ijc.29583","volume":"137","author":"V Schneider","year":"2015","unstructured":"Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A et al. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Int J Cancer 2015; 137: 2083\u20132092.","journal-title":"Int J Cancer"},{"key":"BFbmt2015338_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.imbio.2013.10.008","volume":"219","author":"B Steger","year":"2014","unstructured":"Steger B, Milosevic S, Doessinger G, Reuther S, Liepert A, Braeu M et al. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT. Immunobiology 2014; 219: 247\u2013260.","journal-title":"Immunobiology"},{"key":"BFbmt2015338_CR24","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1200\/JCO.2011.39.6499","volume":"30","author":"JJ Cornelissen","year":"2012","unstructured":"Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol 2012; 30: 2140\u20132146.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015338_CR25","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.2012.46.4222","volume":"31","author":"M L\u00fcbbert","year":"2013","unstructured":"L\u00fcbbert M, Bertz H, M\u00fcller MJ, Finke J . When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome\/acute myeloid leukemia. J Clin Oncol 2013; 31: 822\u2013823.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015338_CR26","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bmt.2013.67","volume":"48","author":"C Ustun","year":"2013","unstructured":"Ustun C, Lazarus HM, Weisdorf D . To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant 2013; 48: 1497\u20131505.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015338_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.bbmt.2014.01.027","volume":"20","author":"RJ Guo","year":"2014","unstructured":"Guo RJ, Atenafu EG, Craddock K, Chang H . Allogeneic hematopoietic cell transplantation may alleviate the negative prognostic impact of monosomal and complex karyotypes on patients with acute myeloid leukemia. Biol Blood Marrow Transplant 2014; 20: 690\u2013695.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015338_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ccr.2011.09.011","volume":"20","author":"L Li","year":"2011","unstructured":"Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia\/acute myeloid leukemia and identifies patients at risk. Cancer Cell 2011; 20: 591\u2013605.","journal-title":"Cancer Cell"},{"key":"BFbmt2015338_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3324\/haematol.2013.089979","volume":"99","author":"S Servais","year":"2014","unstructured":"Servais S, Porcher R, Xhaard A, Robin M, Masson E, Larghero J et al. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related\/unrelated donors. Haematologica 2014; 99: 519\u2013526.","journal-title":"Haematologica"},{"key":"BFbmt2015338_CR30","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.23375","volume":"112","author":"M Sorror","year":"2008","unstructured":"Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992\u20132001.","journal-title":"Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015338","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:15:38Z","timestamp":1648062938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFbmt2015338"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.338","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]},"assertion":[{"value":"4 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest. JF received research grants and speakers honoraries from Medac, Noevii Biotech, Novartis and Riemser.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}